Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Price Crosses Above Fifty Day Moving Average – Should You Sell?

Shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.62 and traded as high as $0.7176. Galmed Pharmaceuticals shares last traded at $0.6775, with a volume of 115,859 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Galmed Pharmaceuticals Stock Up 9.3%

The stock has a market cap of $3.71 million, a price-to-earnings ratio of -0.55 and a beta of 0.62. The firm’s 50 day moving average is $0.62 and its two-hundred day moving average is $0.74.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Citadel Advisors LLC acquired a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 50,492 shares of the biopharmaceutical company’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 3.05% of Galmed Pharmaceuticals as of its most recent SEC filing. Institutional investors own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.